Develops antibody medicines for people with alopecia areata and other autoimmune and inflammatory diseases.
$53.7M
10-K for FY2025, filed Mar 10, 2026
$53.7M ↗Yes. It kept 55 cents of every revenue dollar as net income in FY2025, but spent more cash than it brought in: free cash flow was −$33.5M.
10-Q for Q3 FY2026, filed Nov 4, 2026
−$8.9MView ↗
8-K, filed Jul 13, 2026
On July 13, 2026, the Company announced topline results from the Part B of the SIGNAL-AA Phase 2a signal finding clinical trial evaluating…View ↗
Growing. Revenue grew 58% in 4 years, from $34M in FY2021 to $53.7M in FY2025, about 12% a year.
A shift to immune-disease biologics
The older report described genetic medicines for rare genetic diseases, including gene editing, gene therapy and antibody-producing gene therapy. The latest report focuses on antibody medicines for autoimmune and inflammatory diseases, led by bempikibart for alopecia areata.
10-K for FY2022, filed Mar 9, 2023We are a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with…View ↗
Loading...